Association of Tumor PD-L1 Expression with the T790M Mutation and Progression-Free Survival in Patients with EGFR-Mutant Non-Small Cell Lung Cancer Receiving EGFR-TKI Therapy.
Minehiko InomataKenji AzechiNaoki TakataKana HayashiKotaro TokuiChihiro TakaSeisuke OkazawaKenta KambaraShingo ImanishiToshiro MiwaRyuji HayashiShoko MatsuiKazuyuki TobePublished in: Diagnostics (Basel, Switzerland) (2020)
Patients with negative tumor PD-L1 expression showed longer PFS and a higher proportion of acquisition of T790M mutation of EGFR after first-line treatment with an EGFR-TKI.